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Abstract
Background: Human Immunodeficiency Virus-1 (HIV-1) associated neurocognitive disorders (HANDs) are
accompanied by significant morbidity, which persists despite the use of combined antiretroviral therapy (cART).
While activated microglia play a role in pathogenesis, changes in their immune effector functions, including
phagocytosis and proinflammatory signaling pathways, are not well understood. We have identified leucine-rich
repeat kinase 2 (LRRK2) as a novel regulator of microglial phagocytosis and activation in an in vitro model of
HANDs, and hypothesize that LRRK2 kinase inhibition will attenuate microglial activation during HANDs.
Methods: We treated BV-2 immortalized mouse microglia cells with the HIV-1 trans activator of transcription (Tat)
protein in the absence or presence of LRRK2 kinase inhibitor (LRRK2i). We used Western blot, qRT-PCR,
immunocytochemistry and latex bead engulfment assays to analyze LRRK2 protein levels, proinflammatory cytokine
and phagocytosis receptor expression, LRRK2 cellular distribution and phagocytosis, respectively. Finally, we utilized
ex vivo microfluidic chambers containing primary hippocampal neurons and BV-2 microglia cells to investigate
microglial phagocytosis of neuronal axons.
Results: We found that Tat-treatment of BV-2 cells induced kinase activity associated phosphorylation of serine 935
on LRRK2 and caused the formation of cytoplasmic LRRK2 inclusions. LRRK2i decreased Tat-induced
phosphorylation of serine 935 on LRRK2 and inhibited the formation of Tat-induced cytoplasmic LRRK2 inclusions.
LRRK2i also decreased Tat-induced process extension in BV-2 cells. Furthermore, LRRK2i attenuated Tat-induced
cytokine expression and latex bead engulfment. We examined relevant cellular targets in microfluidic chambers and
found that Tat-treated BV-2 microglia cells cleared axonal arbor and engulfed neuronal elements, whereas saline
treated controls did not. LRRK2i was found to protect axons in the presence of Tat-activated microglia, as well as
AnnexinV, a phosphatidylserine-binding protein. In addition, LRRK2i decreased brain-specific angiogenesis inhibitor
1 (BAI1) receptor expression on BV-2 cells after Tat-treatment, a key receptor in phosphatidylserine-mediated
phagocytosis.
Conclusion: Taken together, these results implicate LRRK2 as a key player in microglial inflammation and,
in particular, in the phagocytosis of neuronal elements. These studies show that LRRK2 kinase inhibition may
prove an effective therapeutic strategy for HANDs, as well as other neuroinflammatory conditions.
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Background
Human Immunodeficiency Virus-1 (HIV-1) associated
neurocognitive disorders (HANDs) are a serious and
growing cause of disability despite the use of combin-
ation antiretroviral therapy (cART) [1]. HIV-1 invades
the central nervous system (CNS) early after infection
and targets invading peripheral macrophage and resident
microglia, which serve as a viral reservoir [2,3]. While
cART suppresses viral replication throughout the host,
early viral proteins are still produced in the CNS due
to the presence of integrated proviral DNA [4]. In par-
ticular, the HIV-1 trans activator of transcription (Tat)
protein is produced within the CNS despite adminis-
tration of cART [5,6]. The HIV-1 Tat protein has been
found to mediate damage in the CNS by upregulating
chemotactic gradients that favor monocyte recruitment
with accompanying neurotoxicity [7]. Furthermore, a sin-
gle dose of Tat in the murine CNS can provide a model
for the neuroinflammation, persistent synaptic damage
and neurodegeneration associated with HANDs [8].
Leucine-rich repeat kinase 2 (LRRK2) is a 286 kDa
signaling protein that has many domains, including a
GTPase, a mitogen-activated protein kinase kinase kinase
(MAPKKK) and a WD-40 domain [9]. Several of the
LRRK2 domains are phosphorylated through both auto-
phosphorylation and constitutive phosphorylation [10].
In particular, phosphorylation of serine 935 (pS935) has
been linked to kinase activity in LRRK2 [11], where
LRRK2 kinase inhibition has been shown to decrease
pS935 in HEK 293 cells [12]. The commercially available
LRRK2 kinase inhibitor used in this study is highly
specific for LRRK2, as it was found to inhibit only 12 out
of 442 kinases based on kinase-binding and biochemical
assays [12].
Mutations in LRRK2 have been found to modify
susceptibility to several diseases with inflammatory
components, including Parkinson’s disease (PD), Crohn’s
disease (CD) and leprosy [13-15]. LRRK2 is highly
expressed in immune cells, including monocytes, B-cells
and T-cells, and this expression has been shown to
increase after both lipopolysaccharide (LPS) and lenti-
viral particle treatment in macrophages [16]. Paradoxic-
ally, LRRK2 deficiency exacerbates experimentally
induced colitis in mice [17], suggesting a phenotypic role
for LRRK2 in CD. Conversely, LRRK2 knockout micro-
glia exhibit attenuated microglial inflammation after LPS
exposure, in which microglial activation has been impli-
cated in modulating PD [18,19]. Moreover, LRRK2 has
been found to increase nuclear factor-kappa beta (NF-
κβ) activity in both CD and PD models [20,21]. Thus,
LRRK2 plays an important role in inflammation that may
have opposing effects based on the unique microenviron-
ment and signaling pathways associated with the given
disorder [22].
LRRK2 is a compelling target in understanding neuro-
degeneration, as mutations in LRRK2 are the most com-
mon single gene cause of PD and are found in both
familial and sporadic cases of disease [23,24]. PD is a
neurodegenerative disorder that is characterized by a
loss of dopaminergic neurons in the substantia nigra
(SN). The PD-associated mutation LRRK2(G2019S),
which causes an increase in LRRK2 kinase activity, has
been shown to cause dendritic degeneration and dopa-
minergic neuronal loss in LRRK2(G2019S) transgenic
mice [25]. These animals also exhibited impaired adult
neurogenesis and neurite outgrowth [26]. However,
LRRK2 is not strongly expressed in the SN [27] and
LRRK2 knockout mice were found to have abnormalities
in protein processing in the kidneys and not in the brain
[28]. Therefore, recent studies have focused on the role
of LRRK2 in microglial inflammation, as the SN has the
highest density of microglia in the CNS [29].
Recent studies have implicated LRRK2 in neuroinflam-
mation and microglial inflammatory responses [18,21,30].
The PD-associated mutation, LRRK2(R1441G), which also
alters LRRK2 kinase activity, has been shown to increase
pro-inflammatory cytokine release in microglia, which was
found to induce neurotoxicity [30]. Another publication by
Moehle et al. has implicated LRRK2 in microglial inflam-
matory responses after exposure to LPS [18]. These results
included inhibition of LPS-induced tumor necrosis factor-α
(TNF-α) release, chemotaxis and microglial process exten-
sion after LRRK2 knockdown. A similar study by Kim et al.
indicated that LRRK2 regulates LPS-induced microglial
activation by altering NF-κβ, p38 and Jun N-terminal kin-
ase (JNK) signaling [21].
As the pathogenicity of LRRK2 activation in microglia
during HANDs remains unexplored, and given the neu-
ropathogenic overlaps between HANDs and PD, we
investigated the role of LRRK2 in a novel in vitro model
of HANDs. Phagocytic engulfment has not been studied
in relation to LRRK2, even though LRRK2 has been
linked to Rac-1, a small Rho GTPase that plays a role in
actin remodeling during phagocytosis [31]. Furthermore,
the use of microfluidic chambers utilizes a highly novel
and physiologically relevant technique to study this
phenomenon. As the effects of Tat have been shown to
be reversible [32], preventing pro-inflammatory cytokine
release and increased phagocytosis during HANDs may
be neuroprotective. This has led us to hypothesize that
HIV-1 Tat increases microglial production of pro-
inflammatory cytokines and phagocytosis of synaptic
elements in a LRRK2-dependent manner.
Methods
Cell lines and reagents
We maintained the BV-2 mouse microglia cell line (kind
gift of Dr. Sanjay B. Maggirwar) in 10% fetal bovine
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serum (FBS) (Atlas, Fort Collins, CO, USA, F-0500-A) in
(D)MEM (Cellgro, Manassas, VA, USA 15-013-CV) with
2 mM GlutaMax (Gibco, Grand Island, NY, USA, 35050–
061) and penicillin-streptomycin (Gibco, 15140–122) at
37°C at 5% CO2. We dissected 18-day embryonic rat pups
to obtain hippocampal neurons for our microfluidic co-
culture experiments. We plated and maintained primary
hippocampal neurons in Neurobasal media (Gibco,
21103–049) supplemented with 5% FBS, B27 supplement
(Gibco, 17504–044), 2 mM GlutaMax, and 50uM L-
glutamic acid (Sigma, St. Louis, MO, USA, G5889-
100G). We resuspended and plated BV-2 cells in the
same supplemented Neurobasal media for all co-culture
experiments. We obtained full length HIV-1 Tat101 from
Philip Ray (University of Kentucky) that we used for all
experiments involving Tat exposure. We purchased the
small molecule LRRK2 kinase inhibitor LRRK2-IN-1
(LRRK2i) from Millipore (Billerica, MA, USA, 438193, 1
μM working concentration) and purified AnnexinV from
eBioscience (San Diego, CA, USA BMS306, working con-
centration 1 μg/ml). Unless otherwise noted, we plated
BV-2 cells in poly-D-lysine (Sigma, P1149-100 mg)
coated 12-well plates or on glass coverslips without
penicillin-streptomycin overnight and treated as indi-
cated with 1 μg/ml Tat101, saline vehicle control, di-
methyl sulfoxide (DMSO) vehicle control, or 1 μM
LRRK2i for 12 hours, as indicated by our preliminary
time-course experiments (data not shown). For BV-2 cell
counts, we used a hemocytometer with 0.4% trypan blue
stain (Gibco, 15250).
Western blotting
We harvested cells by scraping into 1X PBS and centrifu-
ging at 7,000 rpm for 1 minute. We resuspended the pellet
in cell lysis buffer with protease inhibitors and lysed it on
ice with periodic vortexing for 30 minutes. We normalized
protein concentration by Bradford assay (BioRad,
Hercules, CA, USA 500–0113, 500–0114, 500–0115). We
mixed 10 μg of sample with loading dye, heated it at 70°C
for 5 minutes, and ran it on a 4% to 15% SDS-PAGE gel
(BioRad, 456–1086) at 100 V for 1 hour. We transferred
the gel onto a polyvinylidene difluoride (PVDF) mem-
brane at 100 V for 1 hour on ice. We blocked membranes
in 5% milk in 1X Tris-buffered saline (TBS) for 1 hour at
room temperature with shaking. We washed membranes
3 times in 1X Tris-buffered saline with 0.1% Triton-X 100
(TBST) . We applied primary antibodies overnight at 4°C
with shaking in 5% milk in 1X TBST at the following
concentrations; rabbit anti-LRRK2 (1:1000) (Epitomics,
Burlingame, CA, USA, 3514–1), rabbit anti-pS935-LRRK2
(1:1000) (Epitomics, 5099–1), β-actin (1:500) (Santa Cruz,
Santa Cruz, CA, USA, sc-47778) . We washed membranes
3 times in 1X TBST. We applied horseradish peroxidase
(HRP)-conjugated secondary antibody (GE Healthcare,
Pittsburgh, PA, USA ) at a concentration of 1:5,000 in 5%
milk in 1X TBST for 1 hour at room temperature with
shaking. We washed membranes and applied enhanced
chemiluminescence (ECL) substrate (Pierce, Rockford,
IL, USA, 32106) for 1 minute. We exposed and devel-
oped membranes on film (Kodak, Rochester, NY, USA,
111–1681).
qRT-PCR
We isolated RNA from BV-2 cells using the RNeasy RNA
isolation kit (Qiagen, Valencia, CA, USA, 74104). We
synthesized cDNA from 0.5 μg of total RNA using the
SuperScript III First-Strand Synthesis System (Invitrogen,
Carlsbad, CA, USA, 18080–051). We used the TaqMan Uni-
versal PCR Master Mix (Invitrogen, 4304437) with Invitrogen
TaqMan Gene Expression Assay primers and probed for
TNF-α (Mm00443258_m1), IL-6 (Mm00446190_m1),
MCP-1 (Mm00441242_m1), IL-10 (Mm00439614_m1),
IL-4 (Mm00445259_m1), BAI1 (Mm01195143_m1),
Tim4 (Mm00724709_m1) and 18S ribosomal RNA
(Mm03928990_g1) as an internal control. We ran and
measured the samples on an Applied Biosystems (Carlsbad,
CA, USA) StepOnePlus real time PCR machine. We ana-
lyzed relative target gene levels by comparing the fold
change of delta-delta threshold cycle to the control after
normalization to 18S ribosomal RNA.
Immunocytochemistry
We adapted our immunocytochemistry (ICC) protocol
from Glynn et al. [33]. Briefly, we fixed the cells in a so-
lution of 4% paraformaldehyde, 4% sucrose in 1x PBS at
4C for 10 minutes. We then treated the fixed cells
with 100 mM glycine in 1x PBS and washed in 1x PBS
for 5 minutes. We prepared the primary antibodies in
3% BSA (Sigma, A3294-50 G) in 1x PBS at the follow-
ing concentrations: rat anti CD11b 1:200 (Serotech,
MCA711), mouse anti Tau5 1:500 (Calbiochem,
577801), rabbit anti Synapsin-1 1:500 (Cell Signaling,
5297S), and rabbit anti LRRK2 1:500 (Novus, St.
Charles, MO, USA, NB300-268). We incubated in the
fixed cells in the primary antibody solution for 1 hour,
then washed 4 times with 3% BSA, 1x PBS for five min-
utes apiece. We prepared alexa fluor secondary anti-
bodies (Molecular Probes, Eugene, OR, USA) in 3%
BSA, 1x PBS at 1:500, and incubated the cells in sec-
ondary antibody for 30 minutes. We then washed the
cells 4 times in 1x PBS for five minutes apiece, before
mounting them on glass slides using the Prolong Gold
with 4',6-diamidino-2-phenylindole (DAPI) mounting
agent (Life Technologies, Carlsbad, CA, USA, P36935).
Latex bead-based phagocytosis assays
We exposed experimentally-treated BV-2 cells to 0.8 μm
average diameter deep blue dyed uncharged latex beads
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(Sigma, L1398) for 1.5 hours, after which we washed,
scraped, and sonicated the cell/bead suspension. We
measured the absorbance of the resulting solution on a
visible light spectrophotometer at 595 nm to obtain a
quantitative readout for bead phagocytosis. We also
exposed BV-2 cells experimentally treated as indicated
for 6 hours with 1 μm average diameter fluorescent, car-
boxylated latex beads (Invitrogen, F8816) for 45 minutes.
We washed and fixed the cells as in our ICC protocol to
obtain a qualitative readout.
Microfluidic chamber system
We fabricated photoresist molds and polydimethylsiloxane
(PDMS) microfluidic chambers as described by Park et al.
[34]. We plasma-cleaned 22 mm square #1.5 coverglass
(Corning, Tewksbury, MA, USA, 2870–22) and submerged
it in 50 μg/ml poly-d-lysine at 37°C overnight. We thor-
oughly washed and dried the glass and assembled the
chambers by placing the molded PDMS on top of the glass
and allowing it to seal. We then filled the chamber with
media in the order described by Park. After removing the
media, we added 20 μl of a 3.5 × 106 hippocampal cells/ml
cell suspension to the upper left well of the chamber. We
allowed the cells to attach for 15 minutes, and then filled
the chamber with media as described by Park. We
observed axons crossing the 400 μm barrier by 3 days
in vitro (DIV), with extensive neuritic networks forming by
7 DIV.
All of the chambers we used for the microfluidic
experiments were 7 DIV. We imaged the chambers be-
fore treatment to obtain baseline axonal images and
measurements. We then plated the experimentally trea-
ted BV-2 cells in the axon compartment by carefully re-
moving the media from the axon wells and adding 20 μl
of a 3 × 106 BV-2 cells/ml cell suspension to one of the
axon compartment wells. We allowed the cells to attach
and then filled the chamber with media. We utilized a
media pressure gradient to assure that none of the sol-
uble experimental manipulations diffused to the cell
body compartment. We cultured the chambers for a fur-
ther 14 hours and then obtained post treatment bright-
field images. We then deconstructed the chambers and
fixed the cells with 4% paraformaldehyde (Sigma,
441244), 4% sucrose (EM Science, Gibbstown, NJ, USA,
8510) in 1x PBS for future immunocytochemistry. Based
on pilot experiments with MAP-2 and Tau5 (see below),
by 7 DIV, no MAP-2 positive processes were identified
that traversed the entire 400 μm barrier (data not
shown), suggesting that only axonal processes and
growth cones were present in compartment 2.
Imaging and analysis
For our fluorescent fixed cell ICC, we imaged slides on
an Olympus BX-51 upright microscope equipped with
Qioptic Optigrid optical sectioning hardware (Princeton,
NJ, USA). We imaged the fixed cells with a 40x 0.8NA
air objective with a 0.2 um z-step or using a 20x 0.58NA
air objective with a 0.5 um z-step. We captured images
using a Hamamatsu ORCA-ER camera controlled by
Perkin Elmer Volocity software, and created the repre-
sentative images of the three-dimensional stacks using a
z-projection in the same software. For our live cell
bright-field images, we imaged the microfluidic chambers
on an Olympus IX70 inverted microscope under 10x
Figure 1 LRRK2 kinase inhibition blocks Tat-induced S935
phosphorylation and inflammatory cytokine expression in BV-2
cells. (A) Western blot depicting pS935-LRRK2 and total LRRK2
protein levels 12 hours after saline or Tat-treatment ± LRRK2 kinase
inhibition (LRRK2i). (B) Tat treatment significantly increased
pS935-LRRK2, which was attenuated by LRRK2i. (C) We measured
TNF-α, IL-6, MCP-1 and IL-10 mRNA levels by qRT-PCR 12 hours post
saline or Tat treatment ± LRRK2i. LRRK2i attenuated Tat-induced
TNF-α, IL-6, MCP-1 and IL-10 expression for all groups (*P <0.05,
***P <0.001, one way ANOVA, Newman-Keuls post-test). ANOVA,
analysis of variance; LRRK2, leucine-rich repeat kinase2; pS935,
phosphorylation of serine 935; Tat, trans activator of transcription.
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magnification. We captured the images using a PCO.edge
camera controlled by the NIH image capturing software
Micromanager [35]. We processed the images using NIH
ImageJ [36] image analysis software, with the addition of
the NeuronJ Java plugin for axon length analysis (www.
imagescience.org/meijering/software/neuronj/) [37].
Results
LRRK2 expression in BV-2 microglia cells
In order to study LRRK2 activity in microglia, we utilized
the BV-2 mouse microglia cell line. BV-2 microglia cells
are biochemically similar to microglial cells found in the
murine CNS and grow robustly in culture [38]. We found
that Tat-treatment of BV-2 cells induced the kinase activity
associated pS935 on LRRK2, which was decreased by inhib-
ition of LRRK2i (Figure 1A, B).
LRRK2 kinase inhibition attenuates Tat-induced microglial
cytokine expression
To examine microglial activation in response to HIV-1
Tat protein, we analyzed proinflammatory cytokine
expression through qRT-PCR. TNF-α, IL-6 and
MCP-1, also known as CCL2, were significantly
increased after Tat treatment and attenuated through
LRRK2i (Figure 1C). Tat treatment did not induce
IL-4 expression in BV-2 cells (data not shown). These
particular cytokines were analyzed due to their in-
creased expression in the CNS during HANDs and con-
tribution to neurotoxicity [39,40]. Additionally, MCP-1
is a potent inducer of peripheral monocyte infiltration
into the CNS during neuroinflammation, and also
causes migration of resident microglia [41,42].
Altered LRRK2 cytoplasmic distribution and microglial
process length after HIV-1 Tat exposure
We then examined the effect of Tat and LRRK2i on
LRRK2 distribution within BV-2 cells and on BV-2 cell
morphology. ICC against LRRK2 revealed diffuse stain-
ing throughout the cytoplasm in saline control cells
(Figure 2A). When the BV-2 cells are exposed to Tat,
LRRK2 expression appears to be concentrated in small
1 μm inclusions found throughout the cytoplasm
Figure 2 LRRK2 kinase inhibition prevents the formation of Tat-induced LRRK2 positive inclusions and normalizes process length in
BV-2 cells. We treated BV-2 cells for 12 hours with saline or Tat ± LRRK2i and immunostained for LRRK2 (green). (A) Saline-only treated cells
contain diffuse cytoplasmic LRRK2 expression. (B) Tat-treated cells contain brightly staining LRRK2 positive inclusions (white arrows). (C, D) BV-2
cells treated with LRRK2i and either saline or Tat do not contain the inclusions seen in the Tat alone treated group. (E) Graph showing average
length of longest microglia process in various experimental conditions. We averaged the longest processes from 100 microglia in monoculture
from each condition. Tat-treated microglia had significantly longer processes than saline-treated microglia. LRRK2i normalized the microglia
process length in the presence of Tat and had no effect in the presence of saline (***P <0.001, one way ANOVA, Newman-Keuls post-test). In
order to ensure that the changes in BV-2 cell morphology were not accompanied by changes in cell proliferation or cell death, we performed
total cell counts and trypan blue staining after 12 hours of Tat treatment. We found no statistical difference in total cell number (F) or cell death
(G) after 12 hours of Tat exposure (P = 0.28 and P = 0.24 respectively, Student’s t-test). ANOVA, analysis of variance; LRRK2, leucine-rich repeat
kinase 2; LRRK2i, LRRK2 inhibitor; Tat, trans activator of transcription.
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(Figure 2B). The addition of LRRK2i to the saline trea-
ted condition had no effect on LRRK2 distribution
(Figure 2C), while cytoplasmic inclusions were no
longer observed in the Tat-treated condition after the
addition of LRRK2i (Figure 2D). BV-2 cells morpho-
logically responded to Tat exposure by extending pro-
cesses (Figure 2B), as compared to their normal
amoeboid morphology (Figure 2A). While Tat increased
microglia process length, LRRK2i significantly decreased
process length to that of saline controls (Figure 2D, E).
These results expand on previously published data
showing that LRRK2i attenuates LPS-induced microglia
process extension [18]. Furthermore, BV-2 cell counts
indicated that Tat-treatment did not significantly alter
proliferation (Figure 2F) or cell death (Figure 2G) over
the experimental time course.
Tat-induced microglial phagocytosis of uncharged and
carboxylated latex beads is reduced by LRRK2 kinase
inhibition
In order to ascertain phagocytic capacity within Tat-
treated BV-2 cells, we utilized both uncharged and car-
boxylated latex bead engulfment assays. We found that
Tat treatment significantly increased phagocytosis of
uncharged, blue dyed latex beads by BV-2 cells, as
compared to saline treated controls using a quantita-
tive read-out (Figure 3A). Co-treatment with LRRK2i
decreased Tat-induced phagocytosis of uncharged latex
beads and also decreased basal levels of phagocytosis
in saline controls treated with LRRK2i (Figure 3A).
We also exposed BV-2 cells to fluorescent, carboxy-
lated beads, in which the negative charge on the bead
mimics phosphatidylserine exposure on apoptotic cells
Figure 3 LRRK2 kinase inhibition attenuates Tat-induced microglial phagocytosis of uncharged and carboxylated latex beads. We
treated BV-2 cells with saline or Tat for 12 hours ± LRRK2i and then exposed the cultures to uncharged latex beads for 1.5 hours. (A) LRRK2i
significantly decreased Tat-induced phagocytosis of uncharged latex beads (n = 3 per condition). We then treated BV-2 cells with Tat for 6 hours
and exposed them to carboxylated, fluorescent latex beads for 45 minutes. Cells treated with Tat (C ) contain many more latex beads (red) than
saline treated cells (B ). Treatment with LRRK2i in both the saline (D) and Tat (E) conditions decreased the number of engulfed beads (*P <0.05,
***P <0.001, one way ANOVA, Newman-Keuls post-test). ANOVA, analysis of variance; LRRK2, leucine-rich repeat kinase 2; LRRK2i, leucine-rich
repeat kinase 2 inhibitor; Tat, trans activator of transcription.
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[43-45]. We found that Tat-treated BV-2 cells engulfed
more beads (Figure 3C, red signal) as compared to saline
(Figure 3B) or Tat co-treatment with LRRK2i (Figure 3E).
Furthermore, LRRK2i also decreased carboxylated bead
engulfment in saline controls (Figure 3D), similar to
results seen with uncharged beads (Figure 3A). These
results indicate that treatment with LRRK2i is an ef-
fective way to reduce HIV-1 Tat-induced microglial
phagocytosis, which may be partially mediated by
phosphatidylserine exposure on apoptotic cell targets.
Primary axonal clearance by Tat-treated microglia in
microfluidic chambers is reduced by LRRK2 kinase
inhibition
As our laboratory has previously shown that microglia
engulf neuronal components after exposure to HIV-1
Tat in the murine CNS [8], we used in vitro microfluidic
chambers to model microglial-axonal interactions. We
grew primary hippocampal neurons in microfluidic
chambers that allow for physical and fluidic isolation of
axons from soma. This separation allows us to study
potential microglial phagocytosis of neuronal processes
in the absence of neuronal cell bodies. We grew the
neurons in the chambers for seven days, by which
time they had developed an extensive axonal arbor
(Figure 4, pre treatment). We then plated BV-2 cells
in the presence of various experimental conditions in
the axonal compartment, and co-cultured the cells for
a further 18 hours (Figure 4, post treatment).
BV-2 cells exposed to saline (1 μl/ml), DMSO (1 μl/ml),
or LRRK2i alone (1 μM) did not damage the existing
axonal arbor, as indicated by axon persistence (Figures 4,
5A) and growth (Figures 4, 5B). BV-2 cells exposed to Tat
(1 μg/ml), on the other hand, completely destroyed the
existing axonal arbor and prevented any further axon
growth (Figures 4, 5A, 5B). The lack of remaining axonal
debris indicated microglial phagocytosis of axons. We
confirmed this finding using ICC, with many BV-2 cells in
the Tat treated condition containing Tau5 or Synapsin-1
positive inclusions (Figure 6C, D, E). These inclusions
were not present in the saline (Figure 6A) or DMSO
(Figure 6B) conditions. The addition of LRRK2i (1 μM) to
Tat treated BV-2 cells protected the axons from microglial
clearance (Figures 4, 5B, 5A). When we examined these
cells using ICC, we found the presence of some inclusions
that stained positive for neuronal markers, but these
Figure 4 LRRK2 kinase inhibition protects primary axons from Tat-induced microglial phagocytosis. We co-cultured BV-2 cells along with
various experimental conditions in the axonal compartment of established rat hippocampal primary neuron microfluidic chambers for 18 hours.
We imaged the axonal field before and after treatment to determine the effects of the experimentally treated microglia on the neuronal
structures. The figure shows representative images of axons before and after co-culture with experimentally treated BV-2 cells. Axons exposed to
saline or LRRK2i treated BV-2 cells remain wholly intact, while axons exposed to Tat-treated BV-2 cells are largely destroyed. The lack of axonal
debris indicates the presence of microglial phagocytosis. The addition of LRRK2i partially protects the axon field from the Tat treated BV-2 cells.
LRRK2i, leucine-rich repeat kinase 2 inhibitor; Tat, trans activator of transcription.
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inclusions were much smaller and morphologically differ-
ent from those in the Tat treatment alone (Figure 6F).
Tat-induced axonal phagocytosis is partially dependent
on phosphatidylserine exposure to BV-2 cells
To determine if microglial phagocytosis of axons was
phosphatidylserine dependent, we co-treated BV-2s
with Tat and AnnexinV. AnnexinV (1 μg/ml) protected
the axonal field from the Tat treated BV-2 cells
(Figures 5A, 5B, 7A-B). BV-2 cells treated with both Tat
and AnnexinV did contain neuronal marker positive
inclusions similar to those in the Tat only condition
(Figure 6G), but at a far smaller rate than Tat alone
(data not shown). In order to investigate how LRRK2i
may inhibit phagocytosis based on this result, we mea-
sured the expression of two phosphatidylserine recep-
tors, BAI1 and TIM4, in BV-2 cells. We did not find
any TIM4 expression in BV-2 cells (data not shown).
BAI1 expression increased after Tat treatment, although
not significantly (Figure 7C). LRRK2i significantly
decreased BAI1 expression to control levels in Tat-
treated BV-2 cells (Figure 7C). Taken together, these
results indicate a role for phosphatidylserine receptor
mediated phagocytosis of neuronal components.
Microglia morphology is altered by Tat treatment and
LRRK2i during microfluidic coculture with primary
neuronal axons
Finally, we analyzed the morphology of the experimen-
tally treated microglia in the presence of axons. We
Figure 5 Quantification of the effects of LRRK2i and AnnexinV
on Tat induced neuronal axon elimination, neuronal axon
length, and microglia process length. (A) Approximately 80% of
axons remained in microfluidic chambers after exposure to saline,
DMSO, or LRRK2i alone treated BV-2 cells, where only 20% of axons
remained after the addition of Tat treated BV-2 cells. The addition of
LRRK2i or AnnexinV to Tat treated BV-2 cells significantly increased
survival rate to 63% and 75%, respectively (n = 3 chambers per
condition, *P <0.05, **P <0.01, one way ANOVA, Newman-Keuls
post-test). (B) Axons exposed to Tat-treated BV-2 cells are
significantly shorter post treatment. Axons exposed to either DMSO,
LRRK2i alone, Tat and LRRK2i, or Tat and AnnexinV treated BV-2 cells
exhibited no significant change. Axons exposed to saline treated BV-
2 cells were significantly longer post treatment
(n = a minimum of 30 axons per experimental condition,
***P <0.001, two way ANOVA, Bonferroni post test). (C) Tat treated
microglia had significantly longer processes than saline treated
microglia. LRRK2 kinase inhibition normalized the microglia process
length in the presence of Tat. BV-2 cells exposed to Tat and
AnnexinV were not significantly different from Tat alone
(n = longest process of 100 microglia in co-culture, *P <0.05,
**P <0.01, ***P <0.001, one way ANOVA, Newman-Keuls post-test).
ANOVA, analysis of variance; DMSO dimethyl sulfoxide; LRRK2i,
leucine-rich repeat kinase 2 inhibitor; Tat, trans activator of
transcription.
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found that Tat exposed microglia extended processes
longer than controls, and that this process is inhibited
with the addition of LRRK2i, similar to our findings
in monocultures of BV-2 cells (Figure 5C). Surpris-
ingly, the addition of AnnexinV did not inhibit micro-
glia process extension (Figure 5C), indicating that the
microglia are still activated despite the absence of neur-
onal phagocytosis in this condition.
Discussion
LRRK2 is a large signal transduction protein with a
MAPKKK domain. Mutations in LRRK2 are strongly
linked to Parkinson’s disease (PD) [9]. The principal
finding from our data supports the hypothesis that
LRRK2 regulates microglial activation after exposure to
HIV-1 Tat, affecting both microglial pro-inflammatory
cytokine expression and phagocytosis. This functional
change in microglia may account for synaptic damage,
Figure 6 Tat-treated BV-2 cells cultured with primary axons
contain inclusions of neuronal components that are altered by
LRRK2 kinase inhibition. We immunostained BV-2-neuronal
cultures for the axonal cytoskeletal protein Tau 5 (green), the axonal
terminal protein Synapsin-1 (red), and the microglial membrane
protein CD11b (light blue) after 18 hours of experimental treatment.
Saline (A) and DMSO (B) treated BV-2 cells do not appear to
phagocytose any neuronal components. Tat treated BV-2 cells
(C, D, E) contain Tau-5 and Synapsin-1 positive inclusions, indicative
of axonal phagocytosis (white arrows). Tat exposed BV-2 cells treated
with LRRK2i (F) contain some neuronal inclusions that are much
smaller than Tat exposed alone (white arrowheads), indicating a
stunted phagocytic process. Tat exposed BV-2 cells treated with
AnnexinV (G) contain fewer inclusions than Tat alone, but the
inclusions are the same size as the Tat alone treated condition
(white arrows). LRRK2i, leucine-rich repeat kinase 2 inhibitor; Tat,




Figure 7 Tat-induced microglial phagocytosis of axons is
partially dependent on phosphatidylserine signaling. In order to
determine if Tat-induced BV-2 cell phagocytosis of axons was
phosphatidylserine dependent, we blocked phosphatidylserine
exposure with AnnexinV. (A) Microfluidic chambers are shown
before treatment. (B) The addition of AnnexinV protected the axon
field from Tat-treated BV-2 cells in microfluidic chambers. (C) Using
qRT-PCR, we measured the expression of the phosphatidylserine
receptor BA1 in monoculture BV-2 cells exposed to Tat or saline for
12 hours ± LRRK2i. Tat treatment increased BA1 expression, although
not significantly. LRRK2i significantly decreased BA1 expression in Tat
treated BV-2 cells (*P <0.05, one way ANOVA, Newman-Keuls post-
test). ANOVA, analysis of variance; LRRK2i, leucine-rich repeat kinase
2 inhibitor; Tat, trans activator of transcription.
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which is a cornerstone of the neuropathology observed
in HANDs [46].
While it is known that Tat induces the release of the
pro-inflammatory cytokine TNF-alpha in microglia,
how Tat alters phagocytosis in microglia is not well
understood [47]. Several recent publications from the
Brown group show that preventing microglia phagocytosis
is sufficient to protect neurons exposed to either LPS or
micromolar levels of amyloid beta (Aβ) [48-51]. These
results indicate a primary role of microglial phagocytosis
in certain neurodegenerative and neuroinflammatory con-
ditions. Our in vitro microfluidic co-culture system
mimics these findings in the context of HANDs. A recent
publication indicated that treatment with Tat decreased
phagocytosis of Aβ peptide in primary microglia [52], indi-
cating that microglial phagocytosis may be substrate-
specific during neuroinflammation. These data add an add-
itional dimension of complexity to microglial mechanisms
of neuroinflammation when multiple disorders occur
simultaneously within the CNS and highlight the import-
ance of understanding microglial phagocytosis during
neurodegeneration.
Several recent studies investigating LRRK2 in LPS-
induced microglial activation have shown that LRRK2
knockout and the LRRK2(R1441G) mutation attenuated
and augmented microglial inflammation, respectively
[18,21,30]. Interestingly, phosphorylation of LRRK2 at
S910 and S935 occurs during Toll-like receptor signaling
in bone marrow derived macrophages [53]. Our results
extend these findings to show that Tat treatment also
induces phosphorylation at S935 of LRRK2, suggesting
additional loci for Tat to perturb LRRK2 function in
infiltrating pro-inflammatory macrophages in the CNS.
Furthermore, LRRK2 has been found to form inclusions
when in the presence of LRRK2i in HEK-293 cells [12],
lymphoblastoid cells [11], and rat brain [54]. We did not
observe LRRK2 inclusions in the presence of LRRK2i in
BV-2 cells, which may indicate that this phenomenon is
cell-type specific. However, we did observe LRRK2 aggre-
gation after Tat treatment in BV-2 cells, in the form of
several 1 μm LRRK2-positive vesicles. Recent publications
have linked LRRK2 to the autophagy pathway in macro-
phages [16], kidney [28] and brain [55-57]. Future studies
from our laboratory will focus on the purpose of these
inclusions and whether they represent an altered role for
LRRK2 and the autophagy pathway within these cells.
There is a distinct possibility that some of the axonal
protection we observe with the use of the LRRK2i is
provided by LRRK2 kinase inhibition in the axons them-
selves, and not from the anti-inflammatory effects in the
microglia alone. LRRK2 kinase over-activity, specifically
due to the LRRK2(G2019S) mutation, has been shown
to decrease neurite outgrowth and complexity, in both
in vitro and in vivo models [26,56-59]. It is, therefore,
possible that LRRK2 kinase inhibition may impart some
protection to established axons, but the effect of LRRK2
kinase over-activity or inhibition in established axons in
our paradigms has not yet been directly studied.
Our studies did not attempt to establish a mechanism
for how LRRK2 inhibition may prevent microglia phago-
cytosis. However, the ability of AnnexinV to block
axonal phagocytosis and the decrease in BAI1 expression
in Tat-treated BV-2 cells after LRRK2i treatment indi-
cates that Tat-induced phagocytosis is, at least in part,
phosphatidylserine-dependent. Additionally, while the
role of LRRK2 in effecting the neuronal cytoskeleton has
been well established [58], a recent publication has
implicated LRRK2 more generally in actin cytoskeletal
dynamics [60]. Actin reorganization is critical in micro-
glial phagocytosis, providing a potential mechanism for
the reduced phagocytosis in the LRRK2i treated BV-2
cells [61]. Furthermore, LRRK2 knockdown has been
found to reduce reactive oxygen species production dur-
ing bacterial engulfment in macrophages [20].
These findings provide the basis for future studies, not
only in relation to LRRK2 and phagocytosis, but also to
better understand the mechanisms of neuronal phagocyt-
osis by microglia. These phenomena have been implicated
in several neurodegenerative and neuroinflammatory dis-
eases, such as PD, Alzheimer’s disease and HANDs
[8,50,51]. This work may lead to novel LRRK2-based
therapeutic strategies to inhibit microglial inflammation
and phagocytosis of the neuronal arbor.
Conclusions
LRRK2i limits inflammatory cytokine expression and
phagocytosis of neuronal components by microglia
exposed to HIV-1 Tat. These results implicate LRRK2i
as a potential means for developing an adjunctive therapy
for HANDs, as well as other neuroinflammatory disorders
where LRRK2 may be contributing to pathology.
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